Andrx Relinquishes 180-Day Exclusivity For Wellbutrin Generic, Ceding Ground To Eon
Andrx had filed suit against rival generic maker Eon in Florida, arguing that it was the first-to-file an Abbreviated New Drug Application (ANDA) for Wellbutrin, and therefore entitled to the 180-day market exclusivity period provided by law.
Andrx claimed in the lawsuit that the FDA improperly granted approval of Eon's generic tablets.
Under Hatch-Waxman rules, the first company...
To view the full article, register now.